Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 445 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: GLP 1 Clear all

Conditions: Obesity and Overweight
Interventions: NA-931, Tirzepatide, NA-931 150 mg + no Tirzepatide; Drug
Lead sponsor: Biomed Industries, Inc.; Industry
Eligibility: 19 Years to 80 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 5 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, exenatide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 61
States / cities: Birmingham, Alabama • Goodyear, Arizona • Artesia, California + 54 more

Conditions: Gastric Emptying, Glucagon-Like Peptide-1 Receptor Agonists, Intermittent Fasting, Intraoperative Complication Due to Anesthesia, Respiratory Aspiration of Gastric Contents
Interventions: Ultrasound of gastric contents; Diagnostic Test
Lead sponsor: Wael Saasouh, MD; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Obesity, Status Post Sleeve Gastrectomy
Interventions: Liraglutide; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 12 Years to 20 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes Mellitus, Type 2, Obesity, Gastroparesis
Interventions: GLP-1 medication; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: Not listed
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Weston, Florida • Cleveland, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: albiglutide, liraglutide; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 129
States / cities: Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 108 more

Conditions: Type 1 Diabetes Mellitus
Interventions: Dapagliflozin, Insulin, Liraglutide, Dapagliflozin placebo; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK716155, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
Interventions: Metabolic surgery, Incretin-Based Therapy; Procedure · Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 4
States / cities: Phoenix, Arizona • Indianapolis, Indiana • Rochester, Minnesota + 1 more

Conditions: Type 2 Diabetes Mellitus, Healthy
Interventions: GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose, Saline; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: COPD, Obesity & Overweight, Sarcopenia
Interventions: Tirzepatide; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 40 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obesity and Obesity-related Medical Conditions, Obesity and Overweight, Obesity Prevention, Obesity Recidivism, GLP-1, Ablation Techniques
Interventions: Gastric Fundal Mucosal Ablation (GFMA); Device
Lead sponsor: Dr. Christopher McGowan; Other
Eligibility: 21 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cary, North Carolina

Conditions: Obesity
Interventions: liraglutide, Placebo; Drug · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Overweight, Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 2,539 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 54
States / cities: Pelham, Alabama • Scottsdale, Arizona • Concord, California + 47 more

Conditions: Short Bowel Syndrome
Interventions: NM-002; Drug
Lead sponsor: 9 Meters Biopharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions: Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs); Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Psoriasis, Overweight or Obesity
Interventions: Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 38
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 34 more

Conditions: Type 2 Diabetes, Obesity
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Phoenix, Arizona • Concord, California • Sacramento, California + 17 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Cagrilintide, Semaglutide, Tirzepatide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,023 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 54
States / cities: Pelham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more

Conditions: Prediabetes, Type 2 Diabetes
Interventions: Metformin, Liraglutide, Glargine, Placebo; Drug
Lead sponsor: RISE Study Group; Network
Eligibility: 20 Years to 65 Years
Enrollment: 267 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 4
States / cities: Chicago, Illinois • Indianapolis, Indiana • Seattle, Washington

Conditions: Idiopathic Intracranial Hypertension (IIH)
Interventions: Tirzepatide, Tirzepatide Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Overweight or Obesity
Interventions: None - Observational study; Other
Lead sponsor: American Heart Association; Other
Eligibility: 18 Years and older
Enrollment: 1,000,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2060
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Type 2 Diabetes, Overweight, Obesity
Interventions: Tirzepatide, Placebo; Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 938 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 43
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Huntington Park, California + 39 more

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: NNC9204-0530, liraglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Search by objective public record fields.

Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying

Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy

Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy

A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.

Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes

Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.

Fibrosis Lessens After Metabolic Surgery

Modulation of Human Myocardial Metabolism by GLP-1 Dose Response

GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD

MAINTAIN (Mucosal AblatIoN Therapy After INcretins)

Saxenda: Underlying Mechanisms and Clinical Outcomes

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Proof of Concept Study in Patients With Short Bowel Syndrome

Transformative Research in Diabetic Nephropathy 2.0

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

RISE Adult Medication Study

Tirzepatide in Idiopathic Intracranial Hypertension Trial

Healthy Living BEYOND Weight Study

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight

Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity